In the past decade, the treatment of peritoneal metastases has gained interest from oncologic communities around the world. During the 1990âs, the first pioneering centers began treating patients with hyperthermic intraperitoneal chemotherapy (HIPEC). Prior to HIPEC, patients were treated with palliative support and only guaranteed a few months to live. Today, if a patient with peritoneal metastases is provided with proper treatment, the survival increases to an average of several years and improved outcomes are reported every day. The 2016 PSOGI congressâs mission is to provide clinical and scientific information on peritoneal surface malignancies and to create awareness regarding innovative treatments that will improve the quality of life for patients. The target audience includes healthcare practitioners in the field of surgical oncology, clinical oncology, gastroenterology, radiology, and gynecology. The program will also include a satellite meeting related to nurses in the field.
The 2016 International Congress on Peritoneal Surface Malignancies embraces participation from attendees and encourages interaction with faculty. We are excited to be hosting the 10th meeting in Washington, DC and look forward to your attendance.